Skip to content

Monte Rosa Therapeutics, Inc.

GLUE· Nasdaqxbrl foundCIK 1826457

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -9.95%
Market cap
$792.98M
85.45M shares
Filings
405
$54.37M
Q3 2026+63.5% FY25 yoy
$3.06M
Q3 2026N/M FY25 yoy
-$1.94M
Q3 2026N/M FY25 yoy
-$130.61M
Q3 2026derivedN/M FY25 yoy
$0.03
Q3 2026N/M FY25 yoy
$45.18M
Q3 2026−42.1% FY25 yoy
$792.98M
—
11.3×
1.6×
-21.99%
0.00%

Twelve months to Sep 30, 2026 · derived

Price

$9.2835.20%$5.04past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$123.67MFY 2025
$123.67M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$123,672,000reported
FY 20242024-12-31$75,622,000reported
FY 20232023-12-31$0reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025$0.00—$0.00—80.02M sh+30.1%—
FY2024$0.00—$0.00—61.51M sh+22.6%0.0%
FY2023$0.00—$0.00—50.15M sh+1.6%—
FY2022$0.00—$0.00—49.36M sh+5.9%—
FY2021$0.00—$0.00—46.63M sh+2,666.5%—

Biological products, except diagnostic substances

Monte Rosa Therapeutics, Inc. is the 26th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Monte Rosa Therapeutics, Inc. · CIK 1826457 · Engraved from SEC EDGAR